Aster DM Healthcare Limited
₹683.40+₹4.45 (+0.7%)
Last close · Data as of Oct 30, 2026
- Market cap
- ₹31,356 Cr
- P/E
- 92.8x
- EV / EBITDA
- 78.2x
- Revenue
- ₹2,320 Cr
- Net margin
- 7.7%
- ROCE
- 8.8%
Price chart
Technical chartScreen technicals →-2.0% over the last year
Daily closes.
Go deeper
Technical chart: candles, 9 moving averages, RSI, MACD and drawing tools
Performance
Price change over each period, before dividends.
- 1M
- -1.8%
- 3M
- -16.1%
- 6M
- -2.6%
- 1Y
- -2.0%
- 5Y
- +252.8%
52-week range
Day change +₹4.45 (+0.7%) from ₹679 to ₹683 · Last close Oct 30, 2026
Best weekday to invest, historically
The same weekly amount in ASTERDM, bought on each weekday since 2021.
AI Summary
Indian StockStrengths1
- Strong 5-year revenue CAGR of 21.8%
Concerns1
- Low return on equity of 5.4%
Rule-based from financial data. Not advice.
About the company
Aster DM Healthcare Limited, together with its subsidiaries, provides healthcare services in India. It operates through Hospitals, Clinics, Wholesale Pharmacies, and Others segments. The company operates hospitals, clinic, and in-house pharmacies at the hospitals and clinics. It also offers healthcare consultancy and other services. In addition, the company operates retail pharmacies and optical outlets. Aster DM Healthcare Limited was founded in 1987 and is based in Bengaluru, India.
- Sector
- Healthcare
- Shares outstanding
- 51.7 Cr shares
- ISIN
- INE914M01019
- BSE code
- 540975
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- ₹31,356 Cr
- P/E
- 92.8x
- P/B
- 7.1x
- EV / EBITDA
- 78.2x
- EV / Sales
- 15.9x
- P/S
- 15.4x
- Earnings yield
- 1.1%
- 52-week high
- ₹870.30
- 52-week low
- ₹538.40
Profitability
- Operating margin
- 18.0%
- Net margin
- 7.7%
- EBITDA margin
- 20.3%
- ROE
- 5.4%
- ROCE
- 8.8%
- ROA
- 3.5%
- Dividend payout
- 3819.0%
- Tax rate
- 25.0%
- Other income, % of PBT
- 23.0%
Growth
- RevenueLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹2,320 Cr
- Revenue growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 13.9%
- Revenue CAGR, 5YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 21.8%
- EBITDALatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹414 Cr
- EBITDA growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 20.7%
- Net profit growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 3854.8%
- Net profit CAGR, 5YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 20.8%
- Cash from operationsLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹413 Cr
- CFO growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 67.9%
- Free cash flowLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹92.0 Cr
- Asset growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 10.6%
Solvency and efficiency
- Current ratio
- 7.88
- Debt / Equity
- 0.42
- Debt / Assets
- 0.27
- Debt / EBITDA
- 2.94
- Interest coverage
- 4.41
- Financial leverage
- 1.55
- CFO / Net profit
- 2.63
- Cash / Market cap
- 3.2%
- Cash per share
- ₹19.13
- Asset turnover
- 0.45
- Fixed asset turnover
- 1.53
- Capital intensity
- 0.65
- Debtor days
- 23 days
- Inventory turnover
- 9.36
- Cash conversion cycle
- -139 days
Where the revenue went
Of every ₹100 of FY2025 revenue, ₹268 was left as net profit.
| From | To | Amount |
|---|---|---|
| Sales | Expenses | ₹1,857 Cr |
| Sales | Operating profit | ₹463 Cr |
| Operating profit | Interest | ₹91 Cr |
| Operating profit | Depreciation | ₹145 Cr |
| Operating profit | Profit before tax | ₹227 Cr |
| Other income | Profit before tax | ₹6,061 Cr |
| Profit before tax | Tax and other | ₹79 Cr |
| Profit before tax | Net profit | ₹6,209 Cr |
Revenue and net profit
Revenue grew 13.9% in FY2025; net profit is the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2021 | ₹747 Cr | -₹69 Cr |
| FY2022 | ₹1,116 Cr | ₹90 Cr |
| FY2023 | ₹1,534 Cr | ₹173 Cr |
| FY2024 | ₹2,036 Cr | ₹157 Cr |
| FY2025 | ₹2,320 Cr | ₹6,209 Cr |
Cash flows
FY2025: ₹367 Cr from operations, ₹6,390 Cr free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2021 | ₹42 Cr | ₹4 Cr |
| FY2022 | ₹78 Cr | ₹29 Cr |
| FY2023 | ₹246 Cr | -₹86 Cr |
| FY2024 | ₹413 Cr | ₹71 Cr |
| FY2025 | ₹367 Cr | ₹6,390 Cr |
Growth
Latest fiscal year FY2025 (ending March): each figure with its change over the year before.
- Revenue
- ₹2,320 Cr+13.9%1Y
- Net profit
- ₹6,209 Cr+3,854.8%1Y
- Cash from operations
- ₹367 Cr
- Free cash flow
- ₹6,390 Cr+8,900.0%1Y
- Revenue CAGR, 5Y
- 21.8%
- EBITDA CAGR, 5Y
- 17.2%
- Net profit CAGR, 5Y
- 20.8%
| Year | Revenue | Operating income | EBITDA | Net profit | CFO | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|---|---|
| FY2025 | ₹2,320 Cr | ₹463 Cr | — | ₹6,209 Cr | ₹367 Cr | ₹6,390 Cr | 209.3% | +13.9% | +3854.8% |
Monthly returns
Month-by-month returns of ASTERDM across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Liabilities and equity | ₹4,965 Cr |
| Equity capital | ₹500 Cr |
| Reserves | ₹2,466 Cr |
| Borrowings | ₹1,574 Cr |
| Other liabilities | ₹425 Cr |
| Assets | ₹4,965 Cr |
| Fixed assets | ₹1,760 Cr |
| Capital work in progress | ₹55 Cr |
| Investments | ₹1,009 Cr |
| Other assets | ₹2,140 Cr |
Market cap against peers
8 peers: same sector group, nearest by size.
P/E against peers
ASTERDM trades at 92.8x earnings against a peer median of 52.6x (a 76% premium).
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| Aster DM Healthcare LimitedASTERDMthis companyP/E ↑ premium | ₹31,356 Cr | 92.8x | 7.1x | 5.4% | 78.2x |
| Narayana Hrudayalaya LimitedNH | ₹38,566 Cr | 83.0x | 16.6x | 23.1% | 54.0x |
| Ipca Laboratories Ltd.IPCALAB | ₹38,240 Cr | 39.5x | 5.2x | 8.3% | 32.5x |
| Anthem Biosciences LimitedANTHEM | ₹35,376 Cr | 66.2x | 12.4x | 19.4% | 61.4x |
| Ajanta Pharma Ltd.AJANTPHARM | ₹34,058 Cr | 35.8x | 8.3x | 23.6% | 27.3x |
| Global Health LimitedMEDANTA | ₹31,404 Cr | 59.8x | 8.3x | 16.0% | 37.3x |
| Emcure Pharmaceuticals LimitedEMCURE | ₹29,399 Cr | 67.9x | 9.1x | 8.3% | 53.5x |
| J.B. Chemicals & Pharmaceuticals LtJBCHEPHARM | ₹29,217 Cr | 41.5x | 7.9x | 18.8% | 32.1x |
| Gland Pharma LimitedGLAND | ₹28,321 Cr | 24.5x | 2.8x | 11.6% | 17.3x |
| Peer median | — | 52.6x | 5.9x | 12.1% | 38.3x |
Year-to-date ROI
ASTERDM since 1 January, against earlier years.
Historical volatility
ASTERDM's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, in ₹ crore, grouped into plain-language lines.
Figures in ₹ crore as reported, fiscal years ending March, newest first; the trailing twelve months (TTM) last.
Operating margin by fiscal year
| Date | Operating margin |
|---|---|
| FY2021 | 6.0% |
| FY2022 | 14.0% |
| FY2023 | 19.0% |
| FY2024 | 18.0% |
| FY2025 | 20.0% |
| Line | FY2025 |
|---|---|
| RevenueSales | ₹2,320 Cr |
| Costs | |
| Interest | ₹91 Cr |
| Expenses | ₹1,858 Cr |
| Operating profitOperating Profit | ₹463 Cr |
| Other income and charges | |
| Profit before tax | ₹6,288 Cr |
| Tax | |
| Net profitNet Profit | ₹6,209 Cr |
| Per share |
| Line | FY2025 |
|---|---|
| Liabilities and equityTotal Liabilities | ₹4,965 Cr |
| Equity capitalEquity Capital | ₹500 Cr |
| Reserves | ₹2,466 Cr |
| Borrowings | ₹1,574 Cr |
| Other liabilitiesOther Liabilities | ₹425 Cr |
| AssetsTotal Assets | ₹4,965 Cr |
| Fixed assetsFixed Assets | ₹1,760 Cr |
| Capital work in progressCWIP | ₹55 Cr |
| Investments | ₹1,009 Cr |
| Other assetsOther Assets | ₹2,140 Cr |
| Line | FY2025 |
|---|---|
| Operating cash flowCash from Operating Activity | ₹367 Cr |
| Investing cash flowCash from Investing Activity | ₹6,023 Cr |
| Financing cash flowCash from Financing Activity | -₹6,298 Cr |
| Change in cashNet Cash Flow | ₹92 Cr |
Learn while you research
Academy chapters picked for Aster DM Healthcare Limited and the metrics on this page.
- 01 Taxes on Investments (India)LTCG, STCG, dividend tax, what every Indian investor needs.6 min read
- 02 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 03 Valuation Multiples ExplainedThis stock trades at a P/E of 92.8, learn when high multiples are justified.6 min read
- 04 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
- 05 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
- 06 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read